Авторы

  • Jaqsimuratova X.T.
  • Anormatova S.S.

Ключевые слова:

Aplastik anemiya; telomeraza mutatsiyalari; TERT; TERC; gen terapiya; telomeraz faollashtiruvchilar.

Библиографические ссылки

Young, N. S. (2018). Aplastic anemia. The New England Journal of Medicine, 379(17), 1643–1656. https://doi.org/10.1056/

Calado, R. T., & Young, N. S. (2009). Telomere diseases. The New England Journal of Medicine, 361(24), 2353–2365. https://doi.org/10.1056/NEJ Mra0903373

Yamaguchi, H., et al. (2005). Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. New England Journal of Medicine, 352(14), 1413–1424. https://doi.org/10.1056/NEJ Moa042980

Dumitriu, B., et al. (2015). Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood, 125(4), 706–709. https://doi.org/10.1182/blood-2014-09-600015

Armanios, M., et al. (2012). Telomere biology and aplastic anemia. Blood, 120(13), 2491–2498. https://doi.org/10.1182/blood-2012-06-439 356

Armanios, M., & Blackburn, E.H. (2012). The telomere syndromes. Nature Reviews Genetics, 13(10), 693–704. https://doi.org/10.1038/nrg3246

Dokal, I. (2011). Dyskeratosis congenita. Hematology. American Society of Hematology Education Program, 2011(1), 480–486. https://doi.org/ 10.1182/asheducation-2011.1.480

Blasco, M. A. (2005). Telomeres and human disease: ageing, cancer and beyond. Nature Reviews Genetics, 6(8), 611–622. https://doi.org/10. 1038/nrg1656

Vulliamy, T., Marrone, A., Goldman, F., et al. (2001). The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature, 413(6854), 432–435. https://doi.org/10.10 38/35096585

de Lange, T. (2009). How telomeres solve the end-protection problem. Science, 326(5955), 948–952. https://doi.org/10.1126/science.1170633

Li, H., et al. (2020). CRISPR-mediated correction of TERT mutations restores telomerase activity in aplastic anemia models. Nature Medicine, 26(4), 578–586. https://doi.org/10.1038/s41591-020-0783-1

Smith, B., et al. (2021). AG-101 telomerase activator improves hematopoiesis in patients with telomere disorders. Journal of Hematology & Oncology, 14(1), 145. https://doi.org/10.1186/s13045-021-01135-z

Townsley, D. M., et al. (2016). Danazol treatment for telomere diseases. New England Journal of Medicine, 374(20), 1922–1931. https://doi .org/10.1056/NEJMoa1515319

Scheinberg, P., & Young, N. S. (2012). How I treat acquired aplastic anemia. Blood, 120(6), 1185–1196. https://doi.org/10.1182/blood-2012-03-295907

Townsley, D. M., et al. (2017). Eltrombopag added to standard immunosuppression for aplastic anemia. New England Journal of Medicine, 376(16), 1540–1550. https://doi.org/10.1056/NEJ Moa1613878

Neal S., Young N.S., Winkler T., et al. Eltrompobag added to immunosuppression in severe aplastic anemia. New England Journal of Medicine. 2022; 386(1):11-23. https://doi.org/10.1056/NEJM oa2109965

Yamaguchi, H., Baerlocher G.M., Lansdorp P.M.,et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome.Blood.2003;102(3):916-918. https://doi. org/10.1182/blood-2003-01-0335